Abstract: A substituted guanidine derivative represented by the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, a halogen atom or the like; Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4, Y.sub.5, Y.sub.6 and Y.sub.7, which may be the same or different, are independently a single bond, --CH.sub.2 --, --O--, --CO-- or the like, adjacent members of a group consisting of Y.sub.1 through Y.sub.7 being able to be taken together to represent --CH.dbd.CH--, and at least two of Y.sub.1 through Y.sub.7 being independently a group other than a single bond; Z may be absent, or one or more Zs may be present and are, the same or different, independently a substituent for a hydrogen atom bonded to any of the carbon atoms constituting the ring formed by Y.sub.1 through Y.sub.

Abstract: A novel estrogen derivative represented by the formula: ##STR1## is useful for treating or preventing diseases caused by estrogen deficiency.

Abstract: A compound of formula (1) ##STR1## wherein X.sup.1 is amino or hydroxyl, X.sup.2 is carbonyl and the like R.sup.1 is an alkyl, an aryl and the like, R.sup.2 is hydrogen and the like, and R.sup.3 is an alkyl and the like, or a pharmaceutical acceptable salt thereof is effective for inibiting the production and/or secretion of tumor necrosis factor in a patient in need of such inhibition.

Abstract: Human ciliary neurotrophic factor (human CNTF) mutants, in which at least the amino acid residue corresponding to position 153 of wild type human CNTF has been substituted with another amino acid residue in the amino acid sequence encoding human CNTF, exhibit an activity comparable or superior to that of wild type human CNTF. It is therefore expected that the human CNTF mutants would be effective as drugs with improved side effects such as reduction in appearance of an autoantibody, loss of body weight, anorexia, a dry cough, fatigue, etc.In cytokines having sequence similarity to human CNTF and abundant .alpha. helices (GH, PRL, EPO, G- CSF, LIF, IL-6, IL-2, IL-4, GM-CSF), there are further provided mutants in the D1 cap region.

Abstract: The present invention relates to a sustained release formulation used for treatment or prevention of the diseases, which contains a therapeutically effective substance as an active ingredient, collagen as a drug carrier, and glycosaminoglycan as an additive. The formulation allows controlled release of the therapeutically effective substance.

Abstract: A crystalline (5Z,7E,23S)-26,26,26,27,27,27-hexafluoro-9,10-secocholesta-5,7,10(19)-trie n-1.alpha.,3.beta.,23,25-tetraol monohydrate has an excellent preservation stability, and is therefore useful as a medicine for treating or preventing bone diseases, tumor or psoriasis.

Abstract: An immunoassay plate for an immune complex transfer immunoassay, comprising a well type solid phase and a dip stick type solid phase which can be inserted into said well type solid phase, wherein the dip stick type solid phase is coated with either substance (A) or (B) to be mentioned below and the well type solid phase is coated with the other, remaining substance, and these solid phases are used as the two solid phases to be used for an immune complex transfer immunoassay:(A): a substance having a reactive group which specifically binds to a functional group previously introduced onto a substance, which specifically forms an immune complex with a test substance(B): a substance having a reactive group capable of specifically binding to the test substance in the immune complex, a substance which specifically forms an immune complex with the test substance, or a functional group conjugated in advance with said substance, provided that the moiety which binds to the reactive group of (A) does not bind to the rea

Abstract: A humanized antibody is provided, which is obtained by transplantation of the complementarity determining region of a mouse monoclonal antibody B-B10 specific to a human IL-2 receptor into a human antibody. The antibody has a very low antigenicity, and therefore, it is useful for treatment of carcinoma expressing IL-2 receptor.

Abstract: A substituted guanidine derivative represented by the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, a halogen atom or the like; Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4, Y.sub.5, Y .sub.6 and Y.sub.7, which may be the same or different, are independently a single bond, --CH.sub.2 --, --O--, --CO--or the like, adjacent members of a group consisting of Y.sub.1 through Y.sub.7 being able to be taken together to represent --CH.dbd.CH--, and at least two of Y.sub.1 through Y.sub.7 being independently a group other than a single bond; Z may be absent, or one or more Zs may be present and are, the same or different, independently a substituent for a hydrogen atom bonded to any of the carbon atoms constituting the ring formed by Y.sub.1 through Y.sub.

Abstract: A substituted guanidine derivative represented by the general formula: ##STR1## is useful as a therapeutic or prophylactic agent for diseases caused by the acceleration of the sodium/proton (Na.sup.+ /H.sup.+) exchange transport system, for example, hypertension, arrhythmia, angina pectoris, cardiac hypertrophy, diabetes mellitus, organ disorders associated with ischemia or ischemic reperfusion, cerebroischemic disorders, diseases caused by excessive cell proliferation, or diseases caused by endothelial cell injury.

Abstract: Equipment for intracerebral administration of preparations is composed of a preparation-administering device (1) holding a preparation (2), and a plunger (4) removably arranged in the preparation-administering device adapted to push the preparation held therein toward one end of the preparation-administering device. The intracerebral preparation-administration equipment is inserted into a preparation-introducing guide (5) previously implanted in the head of a patient to introduce the preparation into its guide hole (26). The preparation is then guided to a site of administration through a flexible guide tube (23) communicated with the guide hole of the preparation-introducing guide. The equipment for intracerebral administration of preparations may be composed of a tubular preparation-retaining member (30) having a preparation contained therein, and a holder (32) for holding the tubular preparation-retaining member along with a push rod (31) inserted thereinto as an integral part thereof.

Abstract: An imide compound of the formula: ##STR1## wherein Z is a group of the formula: ##STR2## in which B is a carbonyl group or a sulfonyl group, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each a hydrogen atom or a lower alkyl group, or R.sup.1 and R.sup.2 or R.sup.1 and R.sup.3 may be combined together to make a non-aromatic hydrocarbon ring or R.sup.1 and R.sup.3 may be combined together to make an aromatic ring, said non-aromatic hydrocarbon ring being optionally bridged with a lower alkylene group or an oxygen atom therein and said aromatic ring, said non-aromatic hydrocarbon ring and said lower alkylene group being each optionally substituted with at least one lower alkyl, and n is an integer of 0 or 1;D is a group of the formula:--(CH.sub.2).sub.p --A--(CH.sub.2).sub.

Abstract: The invention provides human- or rat-derived neurotrophic peptides and derivatives thereof, precursor peptides thereof, genes encoding the same, transformants containing recombinant expression vectors bearing the genes, and compositions comprising as an effective ingredient these neurotrophic peptides or derivatives thereof. The neurotrophic peptide or its derivatives of the present invention have a neurotrophic activity and are useful for the treatment of neuro-degenerative disorders and dementia.

Abstract: A novel .beta.-lactam compound of the formula ?1!: ##STR1## or a pharmaceutically acceptable salt thereof, which shows an excellent antibacterial activity against Gram-positive bacteria, especially against methicillin-resistant staphylococci and methicillin-resistant coagulase-negative staphylococci, and a process for producing the same. R.sub.1, R.sub.2, X, Y, Z are as defined in the specifacation.

Abstract: A host-vector system suitable for production of human growth hormone (hGH) and a process for production of hGH using the same are provided. As an hGH expression plasmid, a recombinant DNA wherein a DNA coding for hGH is linked to the 3'-terminal of a DNA containing a promoter region derived from Bacillus brevis is provided, and as a host, especially a mutant Bacillus brevis substantially not exhibiting protease activity to hGH is provided. A microorganism obtained by transforming said host with said hGH expression plasmid efficiently produces hGH when it is cultured.

Abstract: The present invention relates to a 2,3-diaminopropionic acid derivative of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful as a platelet aggregation inhibitor, a cancer metastasis inhibitor, a wound healing agent or a bone resorption inhibitor.

Abstract: A recombinant DNA virus for transfecting an animal cell and bearing a foreign gene and a promoter capable of regulating expression of the foreign gene is completely deleted of the function of E2A gene. The recombinant DNA virus can thus stably transduce the foreign gene into various animal cells, which leads to continuous expression of the foreign gene in the animal cells. The continuous expression of the foreign gene can provide an effective treatment of hereditary disease.

Abstract: There is provided a composition for inhibiting the production or secretion of tumor necrosis factor effective for the treatment of cachexia, septic shock, multiple organ failure, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, osteoarthritis, Behcet disease, systemic lupus erythematosus (SLE), graft versus host disease (GvHD), malaria, acquired immune deficiency syndrome (AIDS), meningitis, hepatitis and Type II diabetes mellitus. The composition comprises a pharmaceutically effective amount of a compound of formula (1).

Abstract: Tricyclic quinoxalinediones of the formula: ##STR1## wherein X is alkyl, halogen, cyano, trifluoromethyl, nitro, hydroxy, amino, etc.; R.sup.1 is H, etc.; R.sup.2 is H, alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkylalkyl, arylalkyl, substituted arylalkyl, aryl, or substituted aryl; W is H, CO.sub.2 R.sup.3, CO.sub.2 Y, CONR.sup.3 R.sup.4, CONR.sup.3 Y, CON(OR.sup.3)R.sup.4, COR.sup.3, CN, tetrazolyl, or substituted alkyl; R.sup.3 and R.sup.4 independently are H, alkyl, cycloalkyl, alkenyl, alkynyl, etc.

Abstract: Threo-3-(3,4-dihydroxyphenyl)serine exhibits an analgesic effect against acute pains and chronic or continuous pains. Therefore, threo-3-(3,4-dihydroxyphenyl)serine is effective for the treatment of diseases with pains such as postoperative pain, headache, migraine, pains accompanied by rheumatism, post-herpes neuralgia, cancerous pain, pains associated with cervico-omo-brachial syndrome, shoulder periarthritis, spinal distortion, and spondylosis deformans.